Haymaker Acquisition Corp. 4

Description

Haymaker Acquisition Corp. III does not have any significant operations. It intends to acquire and operate a business in the consumer and consumer-related products. The company was incorporated in 2020 and is based in New York, New York.

About

CEO
Mr. Steven J. Heyer
Employees
0
Instrument type
Common Stock
Sector
Financial Services
Industry
Shell Companies
MIC code
XNYS
Address
501 Madison Avenue, New York, NY 10022, United States
Phone
212 616 9600
Website
Chart Image
× Enlarged Chart
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Error: Invalid Earnings JSON format.

Earnings estimate

Number of analysts
Average estimate
Low estimate
High estimate
Last year EPS
[stock_revenue_estimate]
Error: Invalid Growth Estimates JSON format.

Analyst Ratings

Date Firm Action Rating Price Target

Income statement

2021
Fiscal date 2021-12-31
Total reported revenue
Cost of revenue
Gross profit
Operating expense
Research & development
Selling general and admin 3.12M
Other operating expenses
Operating income -3.32M
Non operating interest income
Income
Expense
Other income expense 14.43M
Pretax income 11.11M
Tax provision
Net income 11.11M
Basic EPS
Diluted EPS
Basic average shares
Diluted average shares
EBITDA -18.72M
Net income from continuing op. 11.11M
Minority interests
Preferred stock dividends

Balance sheet

2021 2020
Fiscal date 2021-12-31 2020-12-31
Total assets 317.71M 1,594
Current assets
Cash 130,359 1,594
Cash equivalents
Cash and cash equivalents 130,359 1,594
Other short term investments
Accounts receivable
Other receivables
Inventory
Prepaid assets 320,959
Restricted cash
Assets held for sale
Hedging assets
Other current assets
Non current assets
Properties
Land and improvements
Machinery furniture equipment
Construction in progress
Leases
Accumulated depreciation
Goodwill
Investment properties
Financial assets
Intangible assets
Investments and advances
Other non current assets 317.58M 145,906
Total liabilities 11.39M 122,500
Current liabilities
Accounts payable 281,304
Accrued expenses 1.83M
Short term debt 122,500
Deferred revenue
Tax payable 160,874
Pensions
Other current liabilities
Non current liabilities
Long term debt
Provision for risks and charges 11.11M
Deferred liabilities
Derivative product liabilities 9.78M
Other non current liabilities
Shareholders equity
Common stock 317.50M 750
Retained earnings -22.63M
Other shareholders equity
Total shareholders equity 294.87M 750
Additional paid in capital 24,250
Treasury stock
Minority interest

Cash flow statement

2021
Operating Activities
Net Income11.11M
Depreciation
Deferred Taxes
Stock-Based Compensation
Other Non-Cash Items
Accounts Receivable-300
Accounts Payable281,304
Other Assets & Liabilities
Operating Cash Flow11.39M
Investing Activities
Capital Expenditures
Net Intangibles
Net Acquisitions
Purchase of Investments
Sale of Investments
Investing Cash Flow-317.50M
Financing Activities
Long-Term Debt Issuance41,500
Long-Term Debt Payments-164,000
Other Financing Charges-377,961
Financing Cash Flow310.65M
Other Cash Details
End Cash Position130,359
Income Tax Paid
Interest Paid
Free Cash Flow-1.37M

Top Institutional Holders

Holder Date Reported Shares Value % Held
First Trust Merger Arbitrage ETF Mar 31, 2022 699,440 6.91M 2.20%
First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd Dec 31, 2021 210,399 2.06M 0.66%
RiverPark Fds Tr-RiverPark Short Term High Yield Fd Dec 31, 2021 100,000 980,000 0.31%
Saba Capital Income & Opportunities Fd Jan 31, 2022 47,715 469,515 0.15%
Highland Fds I-NexPoint Merger Arbitrage Fund Dec 31, 2021 39,736 389,412 0.13%
Fidelity NASDAQ Composite Index Fund Feb 28, 2022 13,079 128,697 0.04%
FPA Funds Tr-FPA Crescent Fund Dec 31, 2021 7,337 71,902 0.02%
First Tr Exchange Traded Fd-First Trust Multi-Strategy Fd Mar 31, 2022 7,546 74,554 0.02%
Frank Fds-Camelot Event Driven Fd Mar 31, 2022 4,580 45,250 0.01%
Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry Article
Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
IRVING, Texas--(BUSINESS WIRE)--Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
Business Wire Neutral
May 26, 2022
Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Article
Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III
IRVING, Texas--(BUSINESS WIRE)--BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing, the combined company's Class A common stock is expected to be traded on the Nasdaq Stock Market (“Nasdaq”) under the
Business Wire Neutral
Dec 13, 2021
Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering Article
Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (the "Company") today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The units will be listed on the NASDAQ Capital Market (“NASDAQ”) and trade under the ticker symbol “HYACU” beginning on March 2, 2021. Each unit consists of one share of Class A common stock and one-fourth of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NASDAQ under the symbols "HYAC" and "HYACW," respectively.
GlobeNewsWire Neutral
Mar 2, 2021
Scroll to Top

Markets

Crypto

how to invest

Who we are